{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:52:10Z","timestamp":1779105130657,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human cervical cancer is the fourth most common carcinoma in women worldwide. However, the emergence of drug resistance calls for continuously developing new anticancer drugs and combination chemotherapy regimens. The present study aimed to investigate the anti-cervical cancer effects of metformin, a first-line therapeutic drug for type 2 diabetes mellitus, and nelfinavir, an HIV protease inhibitor, when used alone or in combination. We found that both metformin and nelfinavir, when used alone, were moderately effective in inhibiting proliferation, inducing apoptosis and suppressing migration and invasion of human cervical cell lines HeLa, SiHa and CaSki. When used in combination, these two drugs acted synergistically to inhibit the growth of human cervical cancer cells <jats:italic>in vitro<\/jats:italic> and cervical cancer cell xenograft <jats:italic>in vivo<\/jats:italic> in nude mice, and suppress cervical cancer cell migration and invasion. The protein expression of phosphoinositide 3-kinase catalytic subunit PI3K(p110\u03b1), which can promote tumor growth, was remarkably downregulated, while the tumor suppressor proteins p53 and p21 were substantially upregulated following the combinational treatment <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. These results suggest that clinical use of metformin and nelfinavir in combination is expected to have synergistic antitumor efficacy and significant potential for the treatment of human cervical cancer.<\/jats:p>","DOI":"10.1038\/srep43373","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T10:41:37Z","timestamp":1488451297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice"],"prefix":"10.1038","volume":"7","author":[{"given":"Chenglai","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinman","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"key":"BFsrep43373_CR1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ajog.2015.10.147","volume":"214","author":"BF Lees","year":"2016","unstructured":"Lees, B. F., Erickson, B. K. & Huh, W. K. Cervical cancer screening: evidence behind the guidelines. Am. J. Obstet. Gynecol. 214, 438\u2013443 (2016).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"BFsrep43373_CR2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.clinthera.2016.02.007","volume":"38","author":"SM Crafton","year":"2016","unstructured":"Crafton, S. M. & Salani, R. Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer. Clin. Ther. 38, 449\u2013458 (2016).","journal-title":"Clin. Ther"},{"key":"BFsrep43373_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fonc.2016.00019","volume":"6","author":"AL Beavis","year":"2016","unstructured":"Beavis, A. L. & Levinson, K. L. Preventing Cervical Cancer in the United States: Barriers and Resolutions for HPV Vaccination. Front. Oncol. 6, 19 (2016).","journal-title":"Front. Oncol"},{"key":"BFsrep43373_CR4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-016-0501-5","volume":"18","author":"MC Macdonald","year":"2016","unstructured":"Macdonald, M. C. & Tidy, J. A. Can We Be Less Radical with Surgery for Early Cervical Cancer? Curr. Oncol. Rep. 18, 16 (2016).","journal-title":"Curr. Oncol. Rep"},{"key":"BFsrep43373_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-1","volume":"14","author":"L Huang","year":"2014","unstructured":"Huang, L. et al. Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients. BMC. Cancer. 14, 1\u20139 (2014).","journal-title":"BMC. Cancer"},{"key":"BFsrep43373_CR6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12885-015-1755-2","volume":"15","author":"LL Holman","year":"2015","unstructured":"Holman, L. L., Ren, Y. & Westin, S. N. Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC. Cancer. 15, 728 (2015).","journal-title":"BMC. Cancer"},{"key":"BFsrep43373_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2015.09.082","volume":"139","author":"R Angioli","year":"2015","unstructured":"Angioli, R. et al. A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. Gynecol. Oncol. 139, 433\u2013438 (2015).","journal-title":"Gynecol. Oncol"},{"key":"BFsrep43373_CR8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0190-9622(98)70124-0","volume":"38","author":"J Krischer","year":"1998","unstructured":"Krischer, J. et al. Regression of Kaposi\u2019s sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad. Dermatol. 38, 594\u2013598 (1998).","journal-title":"J Am Acad. Dermatol"},{"key":"BFsrep43373_CR9","first-page":"401","volume":"3","author":"AP Bhatt","year":"2012","unstructured":"Bhatt, A. P. & Damania, B. AKTivation of PI3K\/AKT\/mTOR signaling pathway by KSHV. Front. Immunol. 3, 401 (2012).","journal-title":"Front. Immunol"},{"key":"BFsrep43373_CR10","first-page":"8256","volume":"65","author":"AK Gupta","year":"2005","unstructured":"Gupta, A. K., Cerniglia, G. J., Mick, R., McKenna, W. G. & Muschel, R. J. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer. Res. 65, 8256\u20138265 (2005).","journal-title":"Res"},{"key":"BFsrep43373_CR11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2015.04.027","volume":"364","author":"T Xiang","year":"2015","unstructured":"Xiang, T., Du, L., Pham, P., Zhu, B. & Jiang, S. Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. Cancer. Lett. 364, 79\u201388 (2015).","journal-title":"Cancer. Lett"},{"key":"BFsrep43373_CR12","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","volume":"69","author":"HA Hirsch","year":"2009","unstructured":"Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. & Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer. Res. 69, 7507\u20137511 (2009).","journal-title":"Cancer. Res"},{"key":"BFsrep43373_CR13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.18632\/oncotarget.248","volume":"2","author":"P Apontes","year":"2011","unstructured":"Apontes, P., Leontieva, O. V., Demidenko, Z. N., Li, F. & Blagosklonny, M. V. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2, 222\u2013233 (2011).","journal-title":"Oncotarget"},{"key":"BFsrep43373_CR14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-008-0015-4","volume":"114","author":"V Stambolic","year":"2009","unstructured":"Stambolic, V., Woodgett, J. R., Fantus, I. G., Pritchard, K. I. & Goodwin, P. J. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast. Cancer. Res. Treat. 114, 387\u2013389 (2009).","journal-title":"Breast. Cancer. Res. Treat"},{"key":"BFsrep43373_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-008-9916-5","volume":"113","author":"KN Phoenix","year":"2009","unstructured":"Phoenix, K. N., Vumbaca, F. & Claffey, K. P. Therapeutic metformin\/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast. Cancer. Res. Treat. 113, 101\u2013111 (2009).","journal-title":"Breast. Cancer. Res. Treat"},{"key":"BFsrep43373_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2012.06.032","volume":"127","author":"X Xiao","year":"2012","unstructured":"Xiao, X. et al. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol. Oncol. 127, 249\u2013255 (2012).","journal-title":"Gynecol. Oncol"},{"key":"BFsrep43373_CR17","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1096\/fj.15-271098","volume":"29","author":"FK Noubissi","year":"2015","unstructured":"Noubissi, F. K., Harkness, T., Alexander, C. M. & Ogle, B. M. Apoptosis-induced cancer cell fusion: a mechanism of breast cancer metastasis. FASEB. J. 29, 4036\u20134045 (2015).","journal-title":"FASEB. J"},{"key":"BFsrep43373_CR18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canlet.2015.04.029","volume":"364","author":"F Xie","year":"2015","unstructured":"Xie, F. et al. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. Cancer. Lett. 364, 106\u2013117 (2015).","journal-title":"Cancer. Lett"},{"key":"BFsrep43373_CR19","first-page":"134","volume":"15","author":"Y-M Feng","year":"2015","unstructured":"Feng, Y.-M. et al. C yproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC. Cancer. 15, 134 (2015).","journal-title":"C"},{"key":"BFsrep43373_CR20","first-page":"10","volume":"372","author":"VV Costantino","year":"2016","unstructured":"Costantino, V. V. et al. Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis. Cancer. Lett. 372, 10\u201323 (2016).","journal-title":"Lett"},{"key":"BFsrep43373_CR21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/CAD.0b013e3283608bc5","volume":"24","author":"W-J Gu","year":"2013","unstructured":"Gu, W.-J. & Liu, H.-L. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2\/B1 siRNA. Anticancer. Drugs. 24, 566\u2013576 (2013).","journal-title":"Anticancer. Drugs"},{"key":"BFsrep43373_CR22","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3892\/ol.2015.3425","volume":"10","author":"K Sun","year":"2015","unstructured":"Sun, K., Tang, X.-H. & Xie, Y.-K. Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression. Oncol. Lett. 10, 1649\u20131654 (2015).","journal-title":"Oncol. Lett"},{"key":"BFsrep43373_CR23","first-page":"899","volume":"22","author":"D Ivanova","year":"2013","unstructured":"Ivanova, D., Bakalova, R., Lazarova, D., Gadjeva, V. & Zhelev, Z. The impact of reactive oxygen species on anticancer therapeutic strategies. Adv. Clin. Exp. Med. 22, 899\u2013908 (2013).","journal-title":"Adv. Clin. Exp. Med"},{"key":"BFsrep43373_CR24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cpr.12226","volume":"48","author":"L-H Wang","year":"2015","unstructured":"Wang, L.-H. et al. SL4, a chalcone-based compound, induces apoptosis in human cancer cells by activation of the ROS\/MAPK signalling pathway. Cell. Prolif. 48, 718\u2013728 (2015).","journal-title":"Cell. Prolif"},{"key":"BFsrep43373_CR25","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/jcmm.12570","volume":"19","author":"W Liu","year":"2015","unstructured":"Liu, W. et al. Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome. J. Cell. Mol. Med. 19, 1949\u20131955 (2015).","journal-title":"J. Cell. Mol. Med."},{"key":"BFsrep43373_CR26","doi-asserted-by":"crossref","first-page":"e92962","DOI":"10.1371\/journal.pone.0092962","volume":"9","author":"Y Dai","year":"2014","unstructured":"Dai, Y. et al. Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels. PLoS. One. 9, e92962 (2014).","journal-title":"PLoS. One"},{"key":"BFsrep43373_CR27","first-page":"263","volume":"347","author":"ZA Knight","year":"2010","unstructured":"Knight, Z. A. Small molecule inhibitors of the PI3-kinase family. Curr Top Microbiol Immunol. 347, 263\u2013278 (2010).","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFsrep43373_CR28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","volume":"113","author":"M Daugan","year":"2016","unstructured":"Daugan, M. et al. Metformin: An anti-diabetic drug to fight cancer. Pharmacol Res. 113, 675\u2013685 (2016).","journal-title":"Pharmacol Res"},{"key":"BFsrep43373_CR29","doi-asserted-by":"crossref","first-page":"20441","DOI":"10.1038\/srep20441","volume":"6","author":"T Hart","year":"2016","unstructured":"Hart, T. et al. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. Sci. Rep. 6, 20441 (2016).","journal-title":"Sci. Rep"},{"key":"BFsrep43373_CR30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","volume":"6","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug, K. et al. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov. 6, 1090\u20131105 (2016).","journal-title":"Cancer Discov"},{"key":"BFsrep43373_CR31","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-12-0007","volume":"48","author":"RJO Dowling","year":"2012","unstructured":"Dowling, R. J. O., Niraula, S., Stambolic, V. & Goodwin, P. J. Metformin in cancer: translational challenges. J. Mol. Endocrinol. 48, R31\u201343 (2012).","journal-title":"J. Mol. Endocrinol."},{"key":"BFsrep43373_CR32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/15384047.2016.1156273","volume":"17","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. Cancer. Biol. Ther. 17, 507\u2013514 (2016).","journal-title":"Cancer. Biol. Ther"},{"key":"BFsrep43373_CR33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.seminoncol.2015.09.009","volume":"43","author":"BM Heckman-Stoddard","year":"2016","unstructured":"Heckman-Stoddard, B. M. et al. Repurposing old drugs to chemoprevention: the case of metformin. Semin. Oncol. 43, 123\u2013133 (2016).","journal-title":"Semin. Oncol"},{"key":"BFsrep43373_CR34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11523-016-0423-z","volume":"11","author":"J Gong","year":"2016","unstructured":"Gong, J. et al. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Target. Oncol. 11, 447\u2013467 (2016).","journal-title":"Target. Oncol"},{"key":"BFsrep43373_CR35","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/sj.bjc.6603435","volume":"95","author":"Y Yang","year":"2006","unstructured":"Yang, Y. et al. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br. J. Cancer. 95, 1653\u20131662 (2006).","journal-title":"Br. J. Cancer"},{"key":"BFsrep43373_CR36","first-page":"1883","volume":"12","author":"A Srirangam","year":"2006","unstructured":"Srirangam, A. et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin. Cancer. Res. 12, 1883\u20131896 (2006).","journal-title":"Res"},{"key":"BFsrep43373_CR37","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1593\/neo.06535","volume":"8","author":"N Pore","year":"2006","unstructured":"Pore, N., Gupta, A. K., Cerniglia, G. J. & Maity, A. HIV protease inhibitors decrease VEGF\/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia. 8, 889\u2013895 (2006).","journal-title":"Neoplasia"},{"key":"BFsrep43373_CR38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/0008-5472.CAN-06-3377","volume":"67","author":"W Jiang","year":"2007","unstructured":"Jiang, W. et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer. Res. 67, 1221\u20131227 (2007).","journal-title":"Cancer. Res"},{"key":"BFsrep43373_CR39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1535-7163.473.3.4","volume":"3","author":"T Ikezoe","year":"2004","unstructured":"Ikezoe, T. et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1\/2. Mol. Cancer. Ther. 3, 473\u2013479 (2004).","journal-title":"Mol. Cancer. Ther"},{"key":"BFsrep43373_CR40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/135965350501000203","volume":"10","author":"M Piccinini","year":"2005","unstructured":"Piccinini, M. et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther. 10, 215\u2013223 (2005).","journal-title":"Antivir. Ther"},{"key":"BFsrep43373_CR41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1166\/jbn.2015.1877","volume":"11","author":"KS Snima","year":"2015","unstructured":"Snima, K. S., Nair, R. S., Nair, S. V., Kamath, C. R. & Lakshmanan, V.-K. Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy. J. Biomed. Nanotechnol. 11, 93\u2013104 (2015).","journal-title":"J. Biomed. Nanotechnol."},{"key":"BFsrep43373_CR42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd.2016.3","volume":"15","author":"RM Webster","year":"2016","unstructured":"Webster, R. M. Combination therapies in oncology. Nat. Rev. Drug. Discov. 15, 81\u201382 (2016).","journal-title":"Nat. Rev. Drug. Discov"},{"key":"BFsrep43373_CR43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1158\/1078-0432.CCR-06-2082","volume":"13","author":"JP Fruehauf","year":"2007","unstructured":"Fruehauf, J. P. & Meyskens, F. L. Reactive oxygen species: a breath of life or death? Clin. Cancer. Res. 13, 789\u2013794 (2007).","journal-title":"Clin. Cancer. Res"},{"key":"BFsrep43373_CR44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati, V., Mahapatra, D. K. & Bharti, S. K. PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur. J. Med. Chem. 109, 314\u2013341 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"BFsrep43373_CR45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","volume":"116","author":"LA Cantrell","year":"2010","unstructured":"Cantrell, L. A. et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation\u2013implications for a novel treatment strategy. Gynecol. Oncol. 116, 92\u201398 (2010).","journal-title":"Gynecol. Oncol"},{"key":"BFsrep43373_CR46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/tx000199t","volume":"14","author":"ZA Stewart","year":"2001","unstructured":"Stewart, Z. A. & Pietenpol, J. A. p53 Signaling and cell cycle checkpoints. Chem. Res. Toxicol. 14, 243\u2013263 (2001).","journal-title":"Chem. Res. Toxicol"},{"key":"BFsrep43373_CR47","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1200\/JCO.2008.16.2347","volume":"26","author":"A Jimeno","year":"2008","unstructured":"Jimeno, A. et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J. Clin. Oncol. 26, 4172\u20134179 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFsrep43373_CR48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol Rev"},{"key":"BFsrep43373_CR49","doi-asserted-by":"crossref","unstructured":"Koltai, T. Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. 4, F1000Research 9 (2015).","DOI":"10.12688\/f1000research.5827.2"},{"key":"BFsrep43373_CR50","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","volume":"11","author":"A Kalender","year":"2010","unstructured":"Kalender, A. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11, 390\u2013401 (2010).","journal-title":"Cell Metab"},{"key":"BFsrep43373_CR51","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bbrc.2015.07.117","volume":"464","author":"P Li","year":"2015","unstructured":"Li, P. et al. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochem Biophys Res Commun 464, 1267\u20131274 (2015)","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep43373_CR52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/135965350601100607","volume":"11","author":"L Hampson","year":"2006","unstructured":"Hampson, L. et al. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro . Antivir Ther. 11, 813\u2013825 (2006).","journal-title":"Antivir Ther"},{"key":"BFsrep43373_CR53","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nprot.2016.028","volume":"11","author":"L Jiang","year":"2016","unstructured":"Jiang, L. et al. Monitoring the progression of cell death and the disassembly of dying cells by flow cytometry. Nat. Protoc. 11, 655\u2013663 (2016).","journal-title":"Nat. Protoc"},{"key":"BFsrep43373_CR54","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3892\/or.2015.4496","volume":"35","author":"K Kato","year":"2016","unstructured":"Kato, K. et al. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. Oncol. Rep. 35, 1582\u20131592 (2016).","journal-title":"Oncol. Rep"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep43373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep43373","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep43373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:04:01Z","timestamp":1671843841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep43373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,22]]}},"alternative-id":["BFsrep43373"],"URL":"https:\/\/doi.org\/10.1038\/srep43373","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]},"assertion":[{"value":"20 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43373"}}